According to a market report by Lucintel, the future of the erythropoietin drug market in Japan looks promising with opportunities in the applications. The erythropoietin drug market in Japan is expected to reach an estimated $7 billion by 2031 with a CAGR of 1.8% from 2025 to 2031. The major drivers for this market are the increasing day by day cases of chronic disease and the growing number of CKD cases.
A more
than 150-page report to understand trends, opportunity and forecast in
erythropoietin drug market in Japan to 2031 by type (biologic and biosimilar),
product (erythropoietin and darbepoetin-alfa), and application (cancer, renal
disease, neurology, and others).
Download
sample by clicking on erythropoietin
drug market in Japan.
Lucintel
forecasts that, within the type category, biologic will remain the larger
segment over the forecast period.
Within the
application category, renal disease will remain the largest segment.
This unique research
report will enable you to make confident business decisions in this globally
competitive marketplace. For a detailed table of contents, contact Lucintel at
+1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost
visit Lucintel's Analytics
Dashboard.
About Lucintel
At Lucintel, we offer solutions for
you growth through game changer ideas and robust market &
unmet needs analysis. We are based in
Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20
years. We are quoted in several publications like the Wall Street Journal,
ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056
Explore Our Latest Publications
Erythropoietin Drug Market in India
Erythropoietin Drug Market in Indonesia
Erythropoietin Drug Market in Malaysia
Erythropoietin Drug Market in China
No comments:
Post a Comment